Remicade infliximab: Phase II data; marketed to treat rheumatoid arthritis (RA) and Crohn’s disease

In a double-blind, placebo-controlled Phase II study of 33 psoriasis patients, 5 and 10 mg/kg of

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE